Tatva Chintan Pharma Chem Ltd — earnings calls

Tatva Chintan reported Q1 FY27 operating revenue of INR1,671 million, up 43% year-on-year and 25% sequentially, with EBITDA of INR323 million, up 86% year-on-year. Management highlighted growth across Phase Transfer Catalysts, Pharma & Agro Intermediates, and Structure Directing Agents segments, along with the first commercial-scale semiconductor product batch being qualified by a customer. The Board approved a new greenfield manufacturing facility involving an investment of approximately INR200 crores.

Tatva Chintan reported Q4 FY26 operating revenue of INR1,341 million, up 24% year-on-year, and EBITDA of INR281 million, up 214% year-on-year, with management attributing the improvement to better product mix and operating leverage. Management described progress across segments including Electrolyte Salts, Structure Directing Agents, Pharma and Agro Intermediates, and a semiconductor chemicals initiative, along with plans for a new greenfield project at Jolva. Management also discussed the impact of rising raw material costs linked to the geopolitical situation and steps taken to pass these costs to customers.